CD276 and cancer: The subgroup analysis based on tumor type showed that B7-H3 expression was significantly associated with worse OS for lung cancer (HR = 1.94; 95%CI = 1.31–2.87, P = 0.001), esophageal cancer (HR = 2.07; 95%CI = 1.19–3.59, P = 0.010) and other cancers including endometrial cancer, breast cancer, cervical cancer, oral cancer, osteosarcoma, hepatocellular cancer, ovarian cancer, RCC, UCB and gallbladder cancer (pooled HR = 1.53; 95% CI = 1.18–1.99; P = 0.001).